Proteon Therapeutics, which is developing a treatment to reduce the failure rates of a dialysis-related procedure, raised $61 million by offering 6.1 million shares at $10, below the range of $12 to $14. Proteon Therapeutics plans to list on the NASDAQ under the symbol PRTO. Proteon Therapeutics initially filed confidentially on 6/25/2014. Stifel and JMP Securities acted as lead managers on the deal.
The article Proteon Therapeutics prices IPO at $10, below the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.